Intrathecal triamcinolone acetonide exerts anti-inflammatory effects on Lewis rat experimental autoimmune neuritis and direct anti-oxidative effects on Schwann cells.
Animals
Anti-Inflammatory Agents
/ administration & dosage
Antigens, CD
/ metabolism
Cell Culture Techniques
Disease Models, Animal
Freund's Adjuvant
/ toxicity
Gene Expression Regulation
/ drug effects
Injections, Spinal
/ methods
Lymph Nodes
/ cytology
Male
Neural Conduction
/ drug effects
Neuritis, Autoimmune, Experimental
/ chemically induced
Oxidative Stress
/ drug effects
Rats
Rats, Inbred Lew
SOXE Transcription Factors
/ metabolism
Schwann Cells
/ drug effects
Thy-1 Antigens
/ metabolism
Triamcinolone Acetonide
/ administration & dosage
Autoimmune neuropathies
Autoimmunity
Experimental autoimmune neuritis
Immunotherapy
Inflammation
Triamcinolone
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
09 Mar 2019
09 Mar 2019
Historique:
received:
13
09
2018
accepted:
25
02
2019
entrez:
11
3
2019
pubmed:
11
3
2019
medline:
16
7
2019
Statut:
epublish
Résumé
Corticosteroids dominate in the treatment of chronic autoimmune neuropathies although long-term use is characterized by devastating side effects. We introduce the intrathecal application of the synthetic steroid triamcinolone (TRIAM) as a novel therapeutic option in experimental autoimmune neuritis in Lewis rats RESULTS: After immunization with neuritogenic P2 peptide, we show a dose-dependent therapeutic effect of one intrathecal injection of 0.3 or 0.6 mg/kg TRIAM on clinical and electrophysiological parameters of neuritis with a lower degree of inflammatory infiltrates (T cells and macrophages) and demyelination in the sciatic nerve. In vitro studies in Schwann cell cultures showed an increased expression of IL-1 receptor antagonist and reduced expression of Toll-like receptor 4 after incubation with TRIAM as well as a protective effect of TRIAM against oxidative stress after H Intrathecal TRIAM application could be a novel immunomodulatory and potentially neuroprotective option for autoimmune neuropathies with a direct effect on Schwann cells.
Sections du résumé
BACKGROUND
BACKGROUND
Corticosteroids dominate in the treatment of chronic autoimmune neuropathies although long-term use is characterized by devastating side effects.
METHODS
METHODS
We introduce the intrathecal application of the synthetic steroid triamcinolone (TRIAM) as a novel therapeutic option in experimental autoimmune neuritis in Lewis rats RESULTS: After immunization with neuritogenic P2 peptide, we show a dose-dependent therapeutic effect of one intrathecal injection of 0.3 or 0.6 mg/kg TRIAM on clinical and electrophysiological parameters of neuritis with a lower degree of inflammatory infiltrates (T cells and macrophages) and demyelination in the sciatic nerve. In vitro studies in Schwann cell cultures showed an increased expression of IL-1 receptor antagonist and reduced expression of Toll-like receptor 4 after incubation with TRIAM as well as a protective effect of TRIAM against oxidative stress after H
CONCLUSION
CONCLUSIONS
Intrathecal TRIAM application could be a novel immunomodulatory and potentially neuroprotective option for autoimmune neuropathies with a direct effect on Schwann cells.
Identifiants
pubmed: 30851725
doi: 10.1186/s12974-019-1445-0
pii: 10.1186/s12974-019-1445-0
pmc: PMC6408772
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antigens, CD
0
SOXE Transcription Factors
0
Sox10 protein, rat
0
Thy-1 Antigens
0
Freund's Adjuvant
9007-81-2
Triamcinolone Acetonide
F446C597KA
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
58Subventions
Organisme : Ruhr-Universität Bochum
ID : Forum
Références
Brain Res. 2000 May 19;865(1):12-6
pubmed: 10814728
J Neuroimmunol. 2001 May 1;116(1):74-82
pubmed: 11311332
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Prog Neurobiol. 2001 Nov;65(4):367-90
pubmed: 11527573
Muscle Nerve. 2003 Sep;28(3):344-52
pubmed: 12929195
Adv Drug Deliv Rev. 2003 Aug 28;55(8):1007-41
pubmed: 12935942
BMC Neurol. 2004 Nov 07;4(1):18
pubmed: 15530171
Eur J Neurol. 2006 Jan;13(1):72-6
pubmed: 16420395
Endocrinology. 2006 Sep;147(9):4339-50
pubmed: 16763064
Endocrinology. 2006 Dec;147(12):5549-56
pubmed: 16946006
J Pharmacol Sci. 2008 Apr;106(4):559-65
pubmed: 18385539
Expert Rev Neurother. 2009 Sep;9(9):1279-87
pubmed: 19769444
J Cereb Blood Flow Metab. 2010 Apr;30(4):801-7
pubmed: 19904284
Glia. 2010 Jun;58(8):954-63
pubmed: 20169622
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD008630
pubmed: 23450584
Clin Neuropharmacol. 2014 Jan-Feb;37(1):22-5
pubmed: 24434528
J Neurol Sci. 2014 May 15;340(1-2):37-43
pubmed: 24607336
Mol Diagn Ther. 2014 Dec;18(6):631-7
pubmed: 24986188
PLoS One. 2014 Aug 08;9(8):e104205
pubmed: 25105500
Spinal Cord. 2015 Feb;53(2):109-13
pubmed: 25224601
Cell Rep. 2015 Mar 24;10(11):1887-98
pubmed: 25801027
Neural Regen Res. 2015 Mar;10(3):377-9
pubmed: 25878582
J Oncol Pharm Pract. 2016 Oct;22(5):659-65
pubmed: 26271105
Retina. 2015 Dec;35(12):2440-9
pubmed: 26352555
CNS Neurosci Ther. 2016 Jan;22(1):74-9
pubmed: 26584946
Ther Adv Neurol Disord. 2016 Jul;9(4):264-8
pubmed: 27366232
Sci Rep. 2016 Aug 23;6:31781
pubmed: 27549422
J Neuroimmunol. 2017 Aug 15;309:58-67
pubmed: 28601289
Neural Plast. 2017;2017:8640970
pubmed: 28928988
Sci Rep. 2018 Jul 25;8(1):11179
pubmed: 30046125
J Neurol Sci. 1982 Nov;56(2-3):173-84
pubmed: 7175545
Cell Immunol. 1995 Oct 1;165(1):65-70
pubmed: 7671325
J Neurosci Res. 1994 Jun 15;38(3):300-13
pubmed: 7932865
Aliment Pharmacol Ther. 1996;10 Suppl 2:81-90; discussion 91-2
pubmed: 8899106
Brain. 1998 Jul;121 ( Pt 7):1257-66
pubmed: 9679778
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10459-64
pubmed: 9724725